Equities research analysts forecast that LeMaitre Vascular Inc (NASDAQ:LMAT) will announce sales of $28.94 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for LeMaitre Vascular’s earnings, with the highest sales estimate coming in at $29.11 million and the lowest estimate coming in at $28.70 million. LeMaitre Vascular posted sales of $27.02 million in the same quarter last year, which would suggest a positive year over year growth rate of 7.1%. The company is expected to announce its next earnings report on Thursday, July 25th.
On average, analysts expect that LeMaitre Vascular will report full-year sales of $114.10 million for the current fiscal year, with estimates ranging from $113.90 million to $114.30 million. For the next year, analysts expect that the business will report sales of $121.69 million, with estimates ranging from $120.10 million to $122.64 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). LeMaitre Vascular had a net margin of 20.92% and a return on equity of 16.76%. The company had revenue of $28.48 million for the quarter, compared to the consensus estimate of $27.94 million. During the same quarter in the prior year, the firm earned $0.19 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 9.6% compared to the same quarter last year.
A number of brokerages recently weighed in on LMAT. BidaskClub upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Zacks Investment Research cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, April 13th. ValuEngine upgraded shares of LeMaitre Vascular from a “sell” rating to a “hold” rating in a research note on Friday, April 26th. Finally, Barrington Research restated a “buy” rating and set a $32.00 price objective on shares of LeMaitre Vascular in a research note on Thursday, May 2nd. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. LeMaitre Vascular presently has an average rating of “Hold” and an average target price of $31.00.
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in LeMaitre Vascular by 2.2% in the fourth quarter. BlackRock Inc. now owns 2,601,309 shares of the medical instruments supplier’s stock worth $61,496,000 after acquiring an additional 56,161 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in LeMaitre Vascular by 1.5% in the first quarter. Conestoga Capital Advisors LLC now owns 1,698,881 shares of the medical instruments supplier’s stock worth $52,665,000 after acquiring an additional 25,750 shares in the last quarter. Ranger Investment Management L.P. raised its position in LeMaitre Vascular by 1.3% in the fourth quarter. Ranger Investment Management L.P. now owns 732,380 shares of the medical instruments supplier’s stock worth $17,313,000 after acquiring an additional 9,688 shares in the last quarter. Bank of New York Mellon Corp raised its position in LeMaitre Vascular by 1.5% in the fourth quarter. Bank of New York Mellon Corp now owns 256,990 shares of the medical instruments supplier’s stock worth $6,075,000 after acquiring an additional 3,841 shares in the last quarter. Finally, Wasatch Advisors Inc. raised its position in LeMaitre Vascular by 54.2% in the first quarter. Wasatch Advisors Inc. now owns 218,784 shares of the medical instruments supplier’s stock worth $6,782,000 after acquiring an additional 76,921 shares in the last quarter. Hedge funds and other institutional investors own 77.10% of the company’s stock.
Shares of NASDAQ LMAT traded up $0.13 during midday trading on Wednesday, reaching $27.98. 232,866 shares of the company traded hands, compared to its average volume of 84,184. LeMaitre Vascular has a 52 week low of $21.79 and a 52 week high of $38.99. The stock’s 50-day moving average is $26.91. The firm has a market capitalization of $547.84 million, a P/E ratio of 33.31, a price-to-earnings-growth ratio of 2.80 and a beta of 1.17.
The firm also recently declared a quarterly dividend, which was paid on Thursday, June 6th. Shareholders of record on Wednesday, May 22nd were given a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 1.22%. The ex-dividend date was Tuesday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.48%.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
See Also: What is Cost of Capital?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.